Doximity Toekomstige groei

Future criteriumcontroles 3/6

Doximity zal naar verwachting groeien in winst en omzet met respectievelijk 9.4% en 9.3% per jaar. De winst per aandeel zal naar verwachting groeien met 10.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 20.5% zijn.

Belangrijke informatie

9.4%

Groei van de winst

10.6%

Groei van de winst per aandeel

Healthcare Services winstgroei	31.0%
Inkomstengroei	9.3%
Toekomstig rendement op eigen vermogen	20.5%
Dekking van analisten	Good
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Recent updates

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Nov 13

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

Aug 10

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Jul 23

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Jul 23

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Jul 01

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Jun 09

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

May 17

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

May 04

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Apr 29

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Apr 16

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Mar 26

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Feb 13

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Jan 04

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Dec 14

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 30

Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Sep 25

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Jul 29

Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Jul 09

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

The Returns At Doximity (NYSE:DOCS) Aren't Growing

Jun 21

Doximity: Digital Health Play With Strong Fundamentals

Jun 21

A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Apr 07

Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return

Mar 20

Doximity: Good Business But Extremely Overvalued

Feb 18

Doximity Q3 Earnings: Disappointing Results

Feb 10

Winst- en omzetgroeiprognoses

NYSE:DOCS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	655	209	273	294	12
3/31/2026	594	179	257	270	17
3/31/2025	540	164	231	237	16
9/30/2024	517	174	217	224	N/A
6/30/2024	494	161	162	168	N/A
3/31/2024	475	148	178	184	N/A
12/31/2023	468	138	162	167	N/A
9/30/2023	448	123	160	165	N/A
6/30/2023	437	119	186	192	N/A
3/31/2023	419	113	173	180	N/A
12/31/2022	402	119	173	180	N/A
9/30/2022	384	141	151	159	N/A
6/30/2022	362	148	131	138	N/A
3/31/2022	344	133	121	127	N/A
12/31/2021	317	107	113	117	N/A
9/30/2021	277	57	110	114	N/A
6/30/2021	243	30	103	107	N/A
3/31/2021	207	22	78	83	N/A
12/31/2020	177	14	48	53	N/A
3/31/2020	116	11	22	26	N/A
3/31/2019	86	1	14	15	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei DOCS ( 9.4% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van DOCS ( 9.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).

Hoge groeiwinsten: De winst van DOCS zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van DOCS ( 9.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van DOCS ( 9.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen DOCS zal naar verwachting over 3 jaar hoog zijn ( 20.5 %)

Doximity Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Price target increased by 8.5% to US$37.21

Price target increased by 7.1% to US$31.64

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Recent updates

Investor sentiment improves as stock rises 20%

Chief Financial Officer notifies of intention to sell stock

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 8.5% to US$37.21

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Now 22% overvalued after recent price rise

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Investor sentiment improves as stock rises 39%

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Price target increased by 7.1% to US$31.64

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

New minor risk - Share price stability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Now 29% undervalued

Now 28% undervalued

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Now 22% undervalued after recent price drop

Chief Financial Officer notifies of intention to sell stock

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Price target increased by 7.2% to US$28.17

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Now 21% undervalued

Investor sentiment improves as stock rises 24%

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $70 million worth of its shares.

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Doximity Launches Docdefender, Expanding Services to Safeguard Physician Privacy

Doximity: Adding Value Using AI But Faces Near-Term Risks

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Insufficient new directors

Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 11% to US$26.91

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 13% to US$32.08

First quarter 2024 earnings: EPS and revenues exceed analyst expectations